A股異動 | 以嶺藥業(002603.SZ)漲停創歷史新高 獲批國家中醫藥服務出口基地
格隆匯3月14日丨以嶺藥業(002603.SZ)今日高開高走,現已漲停,報29.52元創歷史新高,總市值493億元。商務部日前公佈了第二批國家中醫藥服務出口基地名單,石家莊以嶺藥業股份有限公司成功入選。國家中醫藥服務出口基地由商務部、國家中醫藥管理局共同開展建設,旨在進一步加強對中醫藥服務貿易產業的培育、規劃與引導,對於促進中醫藥事業創新發展,優化我國服務貿易機構,打造“中國服務”國家品牌具有重要意義。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.